Climb Bio Reports Phase 2 Budoprutug Data: 70% PLA2R Reduction at Week 12

What happened

Climb Bio reported initial Phase 2 data showing budoprutug reduced PLA2R antibodies by a mean 70% at Week 12 in primary membranous nephropathy. In the 200 mg cohort, 5 of 13 patients, or 38%, achieved immunologic remission by Week 12.

Confirmed

Global impact / market context

A 70% average antibody reduction suggests budoprutug is hitting its biological target in primary membranous nephropathy, a kidney disease. If larger studies confirm this, the drug could advance toward approval and give Climb Bio a valuable product candidate.

Analyst inference

These are early Phase 2 results from a small number of patients, so they show promise but are not proof of effectiveness. Investors typically treat such early data as a signal to watch later results rather than as a reason to revalue the company.

Analyst inference

What to watch

1. Additional primary membranous nephropathy data from the budoprutug program are anticipated in 2027, which will show whether the early antibody reductions hold up in more patients. Confirmed
2. Climb Bio could plan larger later-stage trials of budoprutug, which would require more capital spending and could raise costs before any approval or revenue arrives. Proposed
3. The 600 mg cohort showed 98% mean B-cell suppression at Week 4 versus 74% with 200 mg, so higher doses may matter for effectiveness, but safety must hold as testing expands. Analyst inference

Evidence

• Original source link unavailable